Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 5:25 PM
Ignite Modification Date:
2025-12-24 @ 5:25 PM
NCT ID:
NCT04650750
Eligibility Criteria:
Inclusion Criteria:
1. At least 3 episodes of itch during 2 weeks or less, the itch occurring several times a day, lasting for more than 5 min and being bothersome
2. An intermittent itch over a period of 6 months or more, with a clinical appearance, but with a lower frequency than in (1)
3. People with clear consciousness, without cognitive impairment
4. Those who can cooperate to fill in relevant questionnaires
5. Willing to sign consent forms
6. Blood test indicators: (1) Intact parathyroid hormone (iPTH) \<600 pg/ml (2) Kt/V \>1.2 (3) Serum phosphate \<6 mg/dl
7. Refractory uremic pruritus; The patient failed to respond to following treatments (1) avoiding food containing high amounts of phosphate (2) haemodialysis with a dialysate containing 3.0 or 2.5 mEq/l of calcium (3) changing the dialyser or increasing blood flow
Exclusion Criteria:
1. Be younger than 20 years old.
2. People suffering from diagnosed skin diseases (scabies, drug allergy, atopic dermatitis), severe infections, liver failure, blood diseases or biliary diseases.
3. Patients with abnormal liver and kidney function.
4. People suffering from cognitive dysfunction caused by neurological diseases or mental diseases.
5. People with severe visual impairment, hearing impairment, and physical impairment that affect the scale test.
6. Those who are undergoing other trials.
7. Those who are pregnant or breastfeeding.
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
20 Years
Study:
NCT04650750
Study Brief:
Protocol Section:
NCT04650750